Latest Financial Results
Q3 2021
Quarter Ended Sep 30, 2021
$227.1M
Total revenue of $227.1 million, up 26% from $180.1 million for the prior-year period.
$34.3M
Net income attributable to ApolloMed of $34.3 million, up 105% from $16.7 million for the prior-year period.
$0.74
Earnings per share – diluted of $0.74, up 64% from $0.45 per share for the prior-year period.
For complete information regarding our financials, see our periodic filings